Paper23162016
Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression.
Blich M and 15 others. Arterioscler Thromb Vasc Biol, 2013. Cited by 123 papers, by iCite.
Cite this record
ConductScience Library. Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression. Papers, record 23162016. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23162016
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics29
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Atherosclerosis | Major topic |
| Glucuronidase | Major topic |
| Macrophage Activation | Major topic |
| Macrophages, Peritoneal | Major topic |
| Toll-Like Receptor 2 | Major topic |
| Toll-Like Receptor 4 | Major topic |
| Angina, Stable | |
| Animals | |
| Cell Line | |
| Chemokine CCL2 | |
| Coronary Artery Disease | |
| Disease Progression | |
| Enzyme-Linked Immunosorbent Assay | |
| Gene Expression Regulation | |
| Humans | |
| Immunohistochemistry | |
| Interleukin-1 | |
| Matrix Metalloproteinase 9 | |
| Mice | |
| Mice, Knockout | |
| Myocardial Infarction | |
| Plaque, Atherosclerotic | |
| Polymerase Chain Reaction | |
| Rupture, Spontaneous | |
| Signal Transduction | |
| Time Factors | |
| Transfection | |
| Tumor Necrosis Factor-alpha | |
| Heparanase |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R01 CA106456 | NCI NIH HHS | United States | R01CA106456 | PubMed and NIH |
| CA106456 | NCI NIH HHS | United States | R01CA106456 | PubMed and NIH |
Source NIH RePORTER
References66
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 7287812 | Cultured endothelial cells produce a heparinlike inhibitor of smooth muscle cell growth. | J Cell Biol | 1981 | https://conductscience.org/library/papers/7287812 | PubMed |
| 2 | 15738005 | Conditional signaling by Toll-like receptor 4. | FASEB J | 2005 | https://conductscience.org/library/papers/15738005 | PubMed |
| 3 | 11250066 | Heparanase: a key enzyme involved in cell invasion. | Biochim Biophys Acta | 2001 | https://conductscience.org/library/papers/11250066 | PubMed |
| 4 | 11427519 | Heparanase as mediator of angiogenesis: mode of action. | FASEB J | 2001 | https://conductscience.org/library/papers/11427519 | PubMed |
| 5 | 16631505 | Pathology of the vulnerable plaque. | J Am Coll Cardiol | 2006 | https://conductscience.org/library/papers/16631505 | PubMed |
| 6 | 16607375 | Spatial and temporal heparanase expression in colon mucosa throughout the adenoma-carcinoma sequence. | Mod Pathol | 2006 | https://conductscience.org/library/papers/16607375 | PubMed |
| 7 | 18228298 | Preparation of extracellular matrices produced by cultured corneal endothelial and PF-HR9 endodermal cells. | Curr Protoc Cell Biol | 2001 | https://conductscience.org/library/papers/18228298 | PubMed |
| 8 | 10428300 | Matrix metalloproteinase can facilitate the heparanase-induced promotion of phenotype change in vascular smooth muscle cells. | Atherosclerosis | 1999 | https://conductscience.org/library/papers/10428300 | PubMed |
| 9 | 15647251 | Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. | J Biol Chem | 2005 | https://conductscience.org/library/papers/15647251 | PubMed |
| 10 | 22516446 | Heparanase regulates thrombosis in vascular injury and stent-induced flow disturbance. | J Am Coll Cardiol | 2012 | https://conductscience.org/library/papers/22516446 | PubMed |
| 11 | 14695190 | High heparanase activity in multiple myeloma is associated with elevated microvessel density. | Cancer Res | 2003 | https://conductscience.org/library/papers/14695190 | PubMed |
| 12 | 17635638 | Mammalian heparanase: what is the message? | J Cell Mol Med | 2007 | https://conductscience.org/library/papers/17635638 | PubMed |
| 13 | 21029368 | Pre-clinical and clinical significance of heparanase in Ewing's sarcoma. | J Cell Mol Med | 2011 | https://conductscience.org/library/papers/21029368 | PubMed |
| 14 | 10841569 | Perlecan is required to inhibit thrombosis after deep vascular injury and contributes to endothelial cell-mediated inhibition of intimal hyperplasia. | Proc Natl Acad Sci U S A | 2000 | https://conductscience.org/library/papers/10841569 | PubMed |
| 15 | 11499717 | Nuclear factor kappa-B and the heart. | J Am Coll Cardiol | 2001 | https://conductscience.org/library/papers/11499717 | PubMed |
| 16 | 15790348 | Toll-like receptors, endogenous ligands, and systemic autoimmune disease. | Immunol Rev | 2005 | https://conductscience.org/library/papers/15790348 | PubMed |
| 17 | 7749869 | The response-to-retention hypothesis of early atherogenesis. | Arterioscler Thromb Vasc Biol | 1995 | https://conductscience.org/library/papers/7749869 | PubMed |
| 18 | 15320854 | Inflammation and coronary artery disease. | Curr Vasc Pharmacol | 2003 | https://conductscience.org/library/papers/15320854 | PubMed |
| 19 | 16818787 | Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. | J Immunol | 2006 | https://conductscience.org/library/papers/16818787 | PubMed |
| 20 | 19096032 | Heparanase alters arterial structure, mechanics, and repair following endovascular stenting in mice. | Circ Res | 2009 | https://conductscience.org/library/papers/19096032 | PubMed |
Cited by75
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 123 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42783908 | Recent Advances in the Antihyperlipidemic Activity of Marine Polysaccharides. | Mar Drugs | 2026 | https://conductscience.org/library/papers/42783908 | PubMed |
| 42453335 | Heparanase, Endothelial Dysfunction, and Cardiovascular Risk: The Emerging Role of Vitamin D. | ACS Pharmacol Transl Sci | 2026 | https://conductscience.org/library/papers/42453335 | PubMed |
| 42362731 | Plasma heparan sulfate structural variation and phenotypic heterogeneity in pediatric Acute Respiratory Distress Syndrome. | Sci Rep | 2026 | https://conductscience.org/library/papers/42362731 | PubMed |
| 42290526 | Heparanase gene deficiency suppresses atherosclerosis progression and enhances plaque stability in apolipoprotein E gene knockout mice with diabetes. | Clin Sci (Lond) | 2026 | https://conductscience.org/library/papers/42290526 | PubMed |
| 42147147 | Plasma Heparan Sulfate Structural Variation and Phenotypic Heterogeneity in Pediatric Acute Respiratory Distress Syndrome. | Res Sq | 2026 | https://conductscience.org/library/papers/42147147 | PubMed |
| 41754438 | Molecular Pathways Driving Corneal Neovascularization in Herpes Simplex Keratitis. | Pathogens | 2026 | https://conductscience.org/library/papers/41754438 | PubMed |
| 41604106 | The emerging role of heparanase in cardiovascular diseases: Pathophysiology, clinical outcomes, and therapeutic perspectives. | J Thromb Thrombolysis | 2026 | https://conductscience.org/library/papers/41604106 | PubMed |
| 40899692 | The Pathophysiological Functions of Heparanases: From Evolution, Structural and Tissue-Specific Perspectives. | FASEB J | 2025 | https://conductscience.org/library/papers/40899692 | PubMed |
| 40564001 | Glucocorticoid-Mediated Extracellular Matrix Regulation: Implications for Precision Therapy. | Biomedicines | 2025 | https://conductscience.org/library/papers/40564001 | PubMed |
| 39695102 | Tumor- and host-derived heparanase-2 (Hpa2) attenuates tumorigenicity: role of Hpa2 in macrophage polarization and BRD7 nuclear localization. | Cell Death Dis | 2024 | https://conductscience.org/library/papers/39695102 | PubMed |
| 38892469 | The Uptake of Heparanase into Mast Cells Is Regulated by Its Enzymatic Activity to Degrade Heparan Sulfate. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38892469 | PubMed |
| 38334603 | A New Synthesized Dicarboxylated Oxy-Heparin Efficiently Attenuates Tumor Growth and Metastasis. | Cells | 2024 | https://conductscience.org/library/papers/38334603 | PubMed |
| 37744293 | Heparanase inhibition leads to improvement in patients with acute gastrointestinal injuries induced by sepsis. | World J Gastroenterol | 2023 | https://conductscience.org/library/papers/37744293 | PubMed |
| 37641027 | High temperature influences DNA methylation and transcriptional profiles in sea urchins (Strongylocentrotus intermedius). | BMC Genomics | 2023 | https://conductscience.org/library/papers/37641027 | PubMed |
| 37637421 | Role of heparanase in pulmonary hypertension. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/37637421 | PubMed |
| 37547889 | Heparanase-A single protein with multiple enzymatic and nonenzymatic functions. | Proteoglycan Res | 2023 | https://conductscience.org/library/papers/37547889 | PubMed |
| 36416172 | Flow-Induced Secretion of Endothelial Heparanase Regulates Cardiac Lipoprotein Lipase and Changes Following Diabetes. | J Am Heart Assoc | 2022 | https://conductscience.org/library/papers/36416172 | PubMed |
| 36291066 | Heparanase: A Novel Therapeutic Target for the Treatment of Atherosclerosis. | Cells | 2022 | https://conductscience.org/library/papers/36291066 | PubMed |
| 35563446 | Sulfated Hyaluronan Binds to Heparanase and Blocks Its Enzymatic and Cellular Actions in Carcinoma Cells. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35563446 | PubMed |
| 35036899 | Heparanase as active player in endothelial glycocalyx remodeling. | Matrix Biol Plus | 2022 | https://conductscience.org/library/papers/35036899 | PubMed |
Genes10
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CCL2 | 6347 | PubTator's text mining | https://conductscience.org/library/genes/6347 | NCBI Gene |
| CD163 | 9332 | PubTator's text mining | https://conductscience.org/library/genes/9332 | NCBI Gene |
| HPSE | 10855 | PubTator's text mining | https://conductscience.org/library/genes/10855 | NCBI Gene |
| IL1B | 3553 | PubTator's text mining | https://conductscience.org/library/genes/3553 | NCBI Gene |
| MMP9 | 4318 | PubTator's text mining | https://conductscience.org/library/genes/4318 | NCBI Gene |
| NFKB1 | 4790 | PubTator's text mining | https://conductscience.org/library/genes/4790 | NCBI Gene |
| PIK3R1 | 5295 | PubTator's text mining | https://conductscience.org/library/genes/5295 | NCBI Gene |
| TLR2 | 7097 | PubTator's text mining | https://conductscience.org/library/genes/7097 | NCBI Gene |
| TLR4 | 7099 | PubTator's text mining | https://conductscience.org/library/genes/7099 | NCBI Gene |
| TNF | 7124 | PubTator's text mining | https://conductscience.org/library/genes/7124 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23162016
GET https://conductscience.org/api/papers/v1/23162016/references?page=2